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INTRODUCTION
Breathlessness, dyspnoea and shortness of 
breath are synonymous terms to describe the 
‘subjective experience of breathing discom-
fort that consists of qualitatively distinct sensa-
tions that vary in intensity’.1 2 Chronic breath-
lessness syndrome was recently defined by 
an international consensus as breathlessness 
‘that persists despite optimum treatment for 
the underlying pathophysiology and causes 
disability’.3 4 The pathophysiology and char-
acterisation of breathlessness are described in 
further details in the supplemental material 
available at ESMO Open online. Breathlessness 
is often cited as the most distressing symptom 
experienced by patients with cancer.5 A 2019 
systematic review highlighted six major areas 
of concerns for patients living with breath-
lessness refractory to disease- modifying 
treatments, including physical, emotional, 
spiritual, social, control and context, unifying 
these under the concept of total breathless-
ness.6 In addition to the significant functional 
limitation, breathlessness can have devas-
tating effects on patients’ quality of life (QoL) 
and is associated with a poor prognosis.7
This ESMO Clinical Practice Guideline 
provides an up- to- date, evidence- based 
approach on the assessment and manage-
ment of breathlessness in patients with cancer 
(figure 1). Proper assessment of breathless-
ness involves screening and in- depth evalua-
tion to characterise the symptom and direct 
management. Treatments include inter-
ventions aimed at reversing any underlying 
causes, non- pharmacological and pharmaco-
logical therapies to palliate breathlessness, 
and multimodal approaches. Although the 
focus of this guideline is on patients with 
cancer, the evidence base for breathlessness 
in the oncology setting is relatively limited; 
thus, we have included studies conducted in 
other patient populations, such as chronic 
obstructive pulmonary disease (COPD), if 
the findings are applicable to the oncology 
setting.
PREVALENCE
Breathlessness is highly prevalent, affecting 
between 20% and 70% of patients with 
cancer,8 particularly among patients with 
thoracic malignancies, with advanced stages 
of disease, and in the last weeks of life.9–11
ASSESSMENT
Breathlessness is a subjective experience and 
thus the gold standard for breathlessness 
assessment is based on patient self- report.2 
Breathlessness is easily overlooked when 
relying only on observation of the patient at 
rest (such as in clinic or on the ward) where 
they can appear comfortable. Breathlessness 
is intimately related to physical and emotional 
exertion and patients usually avoid activity 
causing a vicious cycle of deconditioning. The 
response to ‘are you short of breath’ is often 
Highlights
 ► This ESMO Clinical Practice Guideline provides key 
recommendations on the management of breath-
lessness in patients with cancer.
 ► Authorship includes a multidisciplinary group of 
experts from different institutions and countries in 
Europe and worldwide.
 ► Key treatment recommendations are provided, in-
cluding levels of evidence and grades of recommen-
dation where applicable.
 ► Routine assessment of breathlessness and its im-
pact facilitates timely interventions.
 ► Key non- pharmacological measures include fan, 
breathing retraining, mobility aids, education and 
pulmonary rehabilitation.
 ► The main pharmacological option is opioids. 
Supplemental oxygen, non- invasive ventilation and 
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Figure 1 Management of breathlessness in cancer patients in outpatient or inpatient settings aBreathlessness intensity and 
functional impact. bAssessment for causes, severity, episodic nature, emotional and functional impact and caregiver support. 
cIf favourable benefit–risk ratio. dIf SpO2 <90%, however, palliative oxygen is not recommended in patients with resting SpO2 
≥90% [II, D]. eIf hypercapnic respiratory failure. fIf hypoxaemic respiratory failure. gIf other therapies have failed. hEspecially for 
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therefore ‘no’, rendering the breathlessness ‘invisible’.12 
Enquiry should include the activities that the patient has 
reduced or given up because of breathlessness.
Commonly used objective physiological measures 
only have a weak association with subjective sensations 
of breathlessness.13 However, in patients unable to self- 
report breathlessness, vital signs are useful to indicate 
breathlessness distress as well as underlying pathology.14 
In general, lung function tests correlate poorly with the 
symptom of breathlessness and relatively normal values 
do not obviate enquiry about breathlessness.
The multi- faceted experience of breathlessness 
represents another challenge. There is no one tool which 
captures the full experience of breathlessness. Screening 
for breathlessness should include an assessment of inten-
sity with unidimensional tools (eg, Numerical Rating 
Scale (NRS)), and functional impact (eg, modified 
Medical Research Council Breathlessness Scale). Patients 
with a positive screen would require further assessment 
for potential causes, pattern and severity of breathlessness 
(perception), distress due to breathlessness (emotional 
response), functional impairment, and impact on social, 
family, financial and spiritual domains. Patients with 
episodic breathlessness should be asked about the average 
frequency and duration of episodes, the intensity of these 
episodes and potential triggers.
Over 40 patient- reported outcomes for breathless-
ness were identified in the 2007–2008 reviews.15–18 
Many of these questionnaires have multiple questions 
and are designed more for research. A rapid review 
(Medline database; search terms relating to breathless-
ness/dyspnoea and neoplasms/cancer/malignancy and 
measurement/patient- reported outcome measures; date 
limits 2009–2019; single reviewer) failed to show a more 
recent systematic review of breathlessness measurement 
tools usable in cancer. The recommendations therefore 
are unchanged: breathlessness assessment should include 
a unidimensional measure of severity, a measure of multi-
dimensional functional impact and patient interview. 
Details of assessments can be found in supplemental 
material available at ESMO Open online.
Recommendations
 ► Patient- reported outcomes are the gold standard for 
assessment of breathlessness. Physiological assess-
ments may complement but not replace patient 
reports (III, B*).
 ► All patients should be screened for breathlessness 
routinely at all inpatient and outpatient clinical 
encounters (III, B*).
 ► Routine screening for breathlessness should include 
a unidimensional scale of choice and activities that 
patients have stopped or reduced because of breath-
lessness (III, B*).
 ► Patients identified as having chronic breathlessness 
should have a fuller assessment which includes poten-
tial causes, pattern and severity of breathlessness, 
distress due to breathlessness and functional impair-
ment (IV, B*).
 ► For patients with episodic breathlessness, clinicians 
should ask about the intensity, frequency, duration 
and impact of these episodes along with potential trig-
gers (IV, B*).
MANAGEMENT
Treat the underlying cause
Breathlessness may be related to cancer progression, 
cancer therapies and/or acute complications such as infec-
tions or pulmonary embolism. Pre- existing comorbidities 
such as COPD and heart failure may also contribute to 
breathlessness. One of the key strategies in the manage-
ment of breathlessness is to identify and treat any poten-
tial underlying cause(s).19 However, breathlessness is 
often not the primary outcome in randomised clinical 
trials (RCTs) evaluating interventions to treat any under-
lying causes, and validated patient- reported outcomes 
are rarely used to assess breathlessness as a secondary 
outcome. In clinical trials, the Common Toxicity Criteria 
are often used to assess breathlessness instead of patient- 
reported outcomes. A detailed review is beyond the scope 
of this guideline. Table 1 includes management strat-
egies for selected conditions, with further explanations 
provided in supplemental material section 'Treatment of 
underlying causes' available at ESMO Open online.
Non-pharmacological symptomatic interventions
Several non‐pharmacological interventions offer first- line 
treatment options for the management of breathlessness 
and complement use of pharmacological interventions in 
advanced disease. Although studies of sole interventions 
are lacking in cancer, direct evidence exists in chronic 
respiratory disease, and the interventions below are core 
components in most studies of multimodal services (see 
the 'Multimodal interventions section').20
Fan or airflow
Using a hand- held fan to increase airflow towards the 
face represents a simple intervention that patients can 
use to self- manage their breathlessness. Although there 
is a paucity of studies on the use of a fan in patients with 
hypoxaemia and it is unclear if a fan would provide addi-
tional benefit in patients already on supplemental oxygen 
(ie, delivering airflow), the guideline panel supports the 
use of a fan irrespective of the patient’s oxygen satura-
tion given its potential benefit and lack of harm. The 
fan is a cheap, easily- obtained, light, portable and non- 
stigmatising piece of equipment.21 Plausible mechanisms 
of action include cooling nasal receptors and moderating 
afferent signals to the respiratory centre, and increasing 
self- efficacy, particularly around unexpected episodes of 
breathlessness that patients can find difficult to manage.22
A recent review summarised 10 studies of fan therapy 
(median duration 5 min) in 344 patients (159 with 
cancer). Six studies reported a statistically significant 
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Some non- significant findings may relate to underpow-
ered study designs; however, no meta- analysis was under-
taken to increase statistical power. The authors concluded 
limited experimental evidence of efficacy, calling for 
larger trials in more diverse populations and settings.23
A secondary multimethod analysis of qualitative interview 
data explored benefits of a hand- held fan as perceived by 
patients with breathlessness (n=133, n=21 with cancer) and 
their carers (n=72). Most patients with usable data (91/111) 
perceived some or substantial benefit, described in terms 
of shorter recovery time, especially after physical activity. 
Negative perceptions of a few patients included dislike of 
the cooling sensation and embarrassment in public.21 An 
exploratory review of uncontrolled pre- to- post measures in 
16 studies (n=929) where airflow was used either as an inter-
vention (eg, fan) or comparator (eg, as a sham in an oxygen 
trial), found hand- held fan at rest, airflow via nasal cannula 
at rest and airflow during exercise all led to reductions in 
breathlessness intensity.24
Breathing retraining
Altered breathing patterns, including increased respiratory 
rate, apical breathing, excessive accessory muscle recruit-
ment and/or dynamic hyperinflation, can reduce efficiency 
of ventilation, increase work of breathing and cause or exac-
erbate breathlessness.25 Breathing retraining techniques aim 
to improve a patient’s control over their breathing to counter 
these changes. Common techniques include pursed- lip 
breathing, to produce pressure to support the airways and 
improve expiratory flow; diaphragmatic breathing, to reduce 
accessory muscle use, and breathing control or timed 
breathing, which aims to normalise respiratory rate. Indi-
vidual breathing patterns and pathophysiology should be 
considered in their selection.26
A review of 16 trials in COPD (n=1233) found breathing 
retraining over 4–15 weeks improved functional exercise 
capacity, though effects on breathlessness and health- related 
QoL were inconsistent.25 Widespread use as a stand- alone 
intervention was not recommended. A large trial (n=655) in 
patients with incompletely controlled asthma of a self- guided 
breathing retraining intervention, delivered either face- to- 
face or as a digital audio–visual programme plus printed 
booklet, improved QoL over 12 months.27 A single acute 
trial in patients (n=63) with lung cancer (n=32), COPD and 
asthma, who were breathless at rest, found 20 min mindful 
breathing control reduced breathlessness within 5 min. A 
follow- on effect was not studied.28
Mobility aids
Mobility aids help to improve both breathlessness and mobility 
through an increased ventilatory capacity and/or reduced 
metabolic cost.29 30 Despite the absence of studies in patients 
Table 1 Management strategies of selected conditions contributing to breathlessness
Condition Management strategies
Anaemia (symptomatic) Consider transfusion if haemoglobin <70–80 g/L to keep haemoglobin above 70–80 g/L
Asthma/COPD exacerbation Medical optimisation
Cachexia Consider referral to palliative care, dietician and/or physical therapy
Central airway obstruction For proximal lesions, consider endobronchial interventions, such as bronchoscopy with mechanical 
debridement, tumour ablation and airway stent placement
For distal lesions, consider radiotherapy
Cytotoxic chemotherapy- 
induced pulmonary toxicities
Withhold treatment and consider corticosteroids
Immunotherapy- induced 
pulmonary toxicities
Withhold treatment and consider corticosteroids
Heart failure exacerbation Medical optimisation
Lymphangitic carcinomatosis Treatment of underlying malignancy. Consider corticosteroids (anecdotal)
Malignant ascites Paracentesis with or without indwelling catheter
Malignant pleural effusions For patients with a short- life expectancy (<3 months), consider simple thoracentesis
For patients with longer life expectancy, consider tunnelled pleural catheter or chemical pleurodesis; 
both are reasonable options
Malignant pericardial effusion/
tamponade
Pericardiocentesis, pericardiectomy with or without pericardial window
Metabolic acidosis Identify and treat the underlying cause
Pneumonia Anti- infective agents
Pulmonary embolism Anticoagulation
Radiation- induced pneumonitis 
or fibrosis
Consider corticosteroids
Superior vena cava syndrome Treatment of underlying malignancy. Consider corticosteroids (anecdotal)
Tumour embolism Treatment of underlying malignancy
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with cancer, several randomised crossover studies in breath-
less patients with COPD demonstrate that use of a rollator 
improves self- paced walking distance in both indoor31 32 
and outdoor environments,33 especially in patients severely 
limited by breathlessness including those using ambulatory 
oxygen.34 Using a modern ‘draisine’ (bicycle without pedals) 
improved indoor walking distance further still, with the same 
metabolic requirements and breathlessness scores,35 but in 
outdoor environments with obstacles it had a detrimental 
effect on mobility compared with unaided walking.33 All 
the above studies have been conducted over a short time 
period and prolonged satisfaction and benefit should not be 
assumed. If mobility aids are prescribed, a subsequent review 
is recommended.
Education and self-management
For patients receiving curative treatment, education is often 
framed around enhancing recovery and returning to a 
healthy lifestyle. In advanced cancer, where deterioration 
is expected, it can be framed around making the most of 
the present and staying independent for as long as possible. 
Patients should be assured that being breathless is itself not 
dangerous, and that breathlessness is a normal exertional 
response that settles with rest. Even following incremental 
exercise to a symptom- limited maximum, breathlessness 
in people with lung cancer typically recovers within a few 
minutes.36 Advice on positions to aid recovery following 
exertion, or during an episode of breathlessness, can be 
useful.37 A ‘forward- lean’ position may reduce accessory 
muscle work, improving diaphragm function and ventilatory 
capacity.38 Relaxed sitting (with hands or elbows rested on 
thighs) or standing (using a wall as support) and high side 
lying (supporting head and chest) are frequently recom-
mended within breathlessness services.20
Activity pacing (balancing rest and activity) education 
teaches patients to moderate activity behaviour and to avoid 
extremes of rest or activity for optimising the use of available 
energy. A change in routine is often required to avoid ‘boom 
or bust’ situations where patients push themselves too much 
and then need a prolonged period of recovery. Study of 
activity pacing as a standalone intervention for breathlessness 
is lacking, but evidence from its use in cancer- related fatigue39 
and/or pain40 is generally applicable. Distraction using music 
or visualisation has been tested in small studies. An uncon-
trolled study (n=53) found guided imagery with theta music 
reduced breathlessness in patients with advanced cancer,41 
and a retrospective analysis reported positive responses 
to music therapy sessions in a palliative care setting.42 In 
COPD, auditory distraction with music improved the effect 
of exercise training on functional exercise performance, but 
was inconsistent in its short- term effect on exercise testing 
and in reducing breathlessness at rest.43 Bredin et al found 
a nurse- led clinic combining these educational strategies 
with psychological support improved breathlessness, perfor-
mance status and emotional state over 8 weeks in people with 
lung cancer.44
Pulmonary rehabilitation
A rehabilitation approach incorporating exercise should 
be considered for most patients with chronic breathlessness 
to reduce the impact of the symptom on physical function. 
Breathlessness tends to lead towards reduced physical activity, 
which in turn precipitates a downward spiral of decondi-
tioning. Rehabilitation helps to counter this downward spiral 
by improving the physical condition of patients, by exposing 
them to being breathless while staying in control.
As the spiral of deconditioning involves physical inactivity, 
an approach that targets lower limb function and mobility 
is generally helpful. Breathlessness can also limit upper limb 
activities, for example, cooking and shopping, as the muscles 
around the shoulder have a dual role for breathing and 
stability. By improving physical capacity, the relative level of 
ventilatory demand for a fixed activity becomes lower, and 
perceived exertion is reduced. Following exercise training, 
the anxiety related to breathlessness is also reduced allowing 
patients to improve functional performance.45
Both pulmonary and cardiac rehabilitation have a strong 
evidence of effectiveness in improving breathlessness, func-
tional exercise capacity and health- related QoL.46 Though 
most evidence for pulmonary rehabilitation relates to COPD, 
consistent effects are found across other respiratory diseases, 
including lung cancer.47 However, the efficacy of pulmonary 
rehabilitation in patients with advanced cancer is unclear, 
especially when these patients may be too weak to participate 
in exercise sessions. Referral and uptake to these programmes 
should be encouraged. The availability of cancer rehabili-
tation programmes is relatively low, but with accumulating 
evidence of the effect on symptom burden, fitness and QoL48 
and exercise recommendations in national treatment guide-
lines,49 50 this should improve.
Programmes typically incorporate a combination of 
aerobic and resistance training, plus tailored education. In 
general, supervised training leads to a greater exercise work-
load and response47; however, home- based unsupervised 
training is also beneficial if completed regularly. Mind–body 
movement therapies (eg, yoga, tai chi and qigong) may be 
preferred by some patients, and when compared with conven-
tional training modalities, outcomes related to breathlessness 
are similar.51 Low- intensity resistance training using novel 
approaches, for example, neuromuscular muscle stimula-
tion52 or partitioned training, may be suited to patients where 
exertional breathlessness is severely limiting.53 The low venti-
latory demand of these modalities allows the severely breath-
less patient to exercise to help counteract the deconditioning 
associated with physical inactivity.
Complementary therapies
A few, mostly small RCTs have examined the role of 
acupressure or acupuncture in patients with cancer and 
reported short- term benefit on breathlessness.54–56 One 
open- label trial involving 152 patients with lung cancer 
compared prolonged acupuncture (with indwelling 
studs) with morphine or a combination of both and found 
similar reduction on breathlessness but fewer side- effects 
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of 12 clinical trials involving 190 patients with cancer 
and 347 patients with COPD found overall benefit from 
acupuncture on breathlessness severity.57 Additional ther-
apies, including aromatherapy massage, hypnotherapy, 
meditation, reflexology and reiki, may provide limited 
short- term benefit.58 Further high- quality studies are 
needed to examine the risks and benefits of acupuncture 
and other complementary therapies in the long term, 
especially in patients with cancer.
Pharmacological symptomatic interventions
Recommendations on the pharmacological management 
were informed by searches in Medline using the terms 
(dyspnea/dyspnoea/breathlessness) and cancer and, 
in turn, the treatment of interest: (opioid/morphine/
fentanyl), benzodiazepine, steroid, oxygen, high- flow 
oxygen, or (non- invasive/non invasive/NIV), antide-
pressant and cannabinoid. In addition, reference lists of 
major papers and systematic reviews were hand searched.
Opioids
Among the various pharmacological options for breath-
lessness, opioids have been studied the most. However, 
existing randomised trials were generally small and only a 
handful had specifically focused on patients with cancer. 
Although opioids appear to have a pharmacological effect 
on breathlessness, the overall evidence is low and there 
is much uncertainty how they should be used in clinical 
practice.59–62
Efficacy of systemic opioids on chronic breathlessness 
was shown in the latest Cochrane report from 2016 of 12 
RCTs (198 participants of whom 41 (21%) had cancer).59 61 
There is no clear evidence to support use of nebulised 
opioids.61 Compared with placebo, systemic opioids 
decreased breathlessness intensity by a pooled mean of 
0.8 points on a 0–10 NRS,59 which represents between a 
small and a moderate effect size.63 64 Assuming a moderate 
effect size represents clinically meaningful improvement, 
this value is just below this level and suggests that only a 
proportion of patients derived an improvement. Several 
methodological issues may have impacted the study find-
ings. For instance, the trials were mostly small, cross- over 
trials (11 out of 12) with short follow- up.59 61 When the 
cross- over design was taken into account in the statistical 
analysis, the precision around the findings improved.59
Opioid-naïve patients
A multicentre parallel group RCT (<20% with cancer) 
reported that neither 20 mg/day of sustained- release 
morphine nor 5 mg every 8 hours of extended- release (ER) 
oxycodone improved the primary outcome of intensity of 
'breathless now', compared with placebo over 7 days.65 66 
However, several methodological limitations complicate 
its interpretation: ‘rescue’ immediate- release morphine 
(MIR) was available for all patients with higher usage in 
the placebo groups; early termination of the oxycodone 
group; difficulties with enrolment; opioid dosing; and not 
all patients were opioid- naïve. While the best evidence 
for opioids is in people with COPD, a pooled data study 
showed no predictive association of underlying disease,61 
although younger patients and patients with more severe 
breathlessness were more likely to gain benefit.67 Given 
methodological limitations in existing studies, further 
research is needed to examine the efficacy of opioids and 
optimal administration in opioid- naïve patients.
There are no head- to- head comparisons of immediate- 
release (IR) and ER formulations for breathlessness. 
The Therapeutic Goods Administration has extended 
the licence for one ER formulation of oral morphine 
(morphine sulfate pentahydrate) to include chronic 
breathlessness in Australia. A dose range of 10–30 mg per 
24 hours is licensed, with an explicit statement that addi-
tional morphine sulfate IR doses should not be given for 
breathlessness but may be needed for concurrent pain.68
Opioid-tolerant patients
There are few RCTs to inform use of opioids for treatment 
of breathlessness in patients with cancer taking regular 
opioids for pain. A cross- over, placebo- controlled trial 
found that a single dose of subcutaneous morphine given 
at 50% higher than the scheduled 4- hourly dose resulted 
in a significant reduction of breathlessness consistently 
over the first hour compared with placebo among patients 
with cancer.69 In a second dose- comparison study, patients 
with persistent breathlessness were given a dose of MIR at 
25% or 50% more than their usual 4- hourly dose.70 There 
was no difference in the improvement of breathlessness 
between the two groups. Preliminary data from a small 
randomised trial comparing fentanyl buccal tablet with 
morphine sulfate for treatment of episodic breathlessness 
suggested that fentanyl had a faster onset and provided 
greater relief.71 Several small placebo- controlled trials 
have examined the use of prophylactic fentanyl given 
prior to exertion in opioid- tolerant patients with cancer 
and reported a benefit (discussed below).72–74 Taken 
together, the available evidence signals that opioids have 
a positive effect on breathlessness among opioid- tolerant 
individuals, giving justification for further studies to 
examine these findings in confirmatory trials and to 
determine the optimal dose and timing of opioids for 
breathlessness.
Prophylactic use of opioids prior to exertion among opioid-tolerant 
patients
Because breathlessness predictably increases with exer-
tion, the use of IR opioids prior to activity (or indeed, 
the use of sustained- release opioid) may potentially 
reduce this distressing symptom and thereby maximise 
activity level.75 Rapid- onset fentanyl formulations may be 
appealing for this purpose given their fast onset of action 
and ease of administration. To date, only a handful of 
small RCTs have examined the use of opioids in patients 
with cancer for prophylaxis. Small double- blind, placebo- 
controlled studies of subcutaneous fentanyl,72 fentanyl 
pectin nasal spray73 and fentanyl buccal tablet74 showed 
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capacity; however, these studies were not powered for 
between- arm comparisons. Recently, a dose- finding study 
suggested the use of higher proportional dose of fentanyl 
sublingual spray (35%–45% of morphine equivalent daily 
dose (MEDD)) conferred a clinical benefit in contrast to 
a lower dose (15%–25% of MEDD) in the prophylactic 
setting.76 Outside of the cancer setting, two randomised 
trials also suggested that nebulised fentanyl may improve 
dyspnoea during exercise.77 78 Importantly, the long- term 
use of rapid- onset fentanyl has not been examined system-
atically and the risk of addiction with these agents needs 
to be further investigated. Limited use of prophylactic 
opioids should only be considered among patients with 
severe functional impairment and/or distress related to 
specific activities causing breathlessness and when the 
benefits likely outweigh potential risks. Larger pragmatic 
studies are needed to examine how opioids could be used 
on a prophylactic basis to improve episodic breathless-
ness.
Choice of opioid
The panel would like to emphasise that there are signifi-
cant limitations among existing clinical trials on opioids, 
particularly for people with cancer, which contribute to 
variable interpretation of these studies. When formu-
lating treatment recommendations, the panel carefully 
weighed the risks and benefits of opioid therapy based on 
all available literature, while recognising significant varia-
tions in practices across regions. In a patient with severe, 
debilitating chronic breathlessness at rest or provoked 
by minimal exertion despite non- pharmacological 
management, treatment with ER morphine provides the 
smoothest steady- state where the effect size appears to be 
greatest, at least in COPD studies. A starting dose in an 
opioid- naïve patient could be between 5 and 15 mg of ER 
morphine two times a day,79 although the doses may need 
to be lower for selected populations (eg, renal failure). 
Titration should be tailored to the individual starting 
with the lowest possible dose. A placebo- controlled dose 
titration RCT in COPD is expected in 2021.80 Similar to 
pain,81 a rescue dose or IR morphine of about 1/6 of the 
patient’s total daily morphine dose may be considered, if 
needed. Most research evidence pertains to doses equiv-
alent to 10–30 mg oral morphine per day,59 61 82 83 and it 
is unknown if higher doses give further benefit; data are 
awaited.
Most evidence, including the adequately powered 
trials, relates to morphine and to people with non- 
malignant disease. There is emerging evidence for 
fentanyl and adequately powered trials would be useful 
to inform use in people with poor renal function, or 
where different pharmacokinetic profiles may be helpful. 
Theoretically, opioids given at equianalgesic doses are 
expected to provide similar levels of benefits on breath-
lessness; however, some patients may respond better to 
selected opioids. More research is needed to investi-
gate this. All patients starting opioids should be offered 
prophylaxis for constipation with laxatives and, as 
needed, antiemetics. For further discussion of opioid- 
related adverse effects and principles of safe opioid use 
see supplemental material available at ESMO Open online.
Benzodiazepines
Benzodiazepines are frequently used for the relief of 
breathlessness in clinical practice, especially when breath-
lessness is associated with symptoms of anxiety or panic. 
However, there is currently insufficient evidence from 
clinical trials to support the use of benzodiazepines for 
the relief of breathlessness, either in malignant or non- 
malignant disease.84 The Cochrane systematic review of 
Simon et al included eight small RCTs, most of them with 
a unclear risk of bias, that tested the effect of benzodi-
azepines for the relief of breathlessness in adult patients 
with advanced disease, out of which 66 had COPD and 
148 patients had cancer.84 Only one trial showed a signif-
icant reduction of breathlessness intensity in patients 
receiving midazolam in comparison with the morphine 
group, which is conflicting with the result of a second 
study by the same research team.85 86 The other seven 
studies included in the review did not demonstrate any 
significant difference for benzodiazepines compared with 
placebo or morphine. Two additional RCTs have been 
identified both without any significant effect of benzodi-
azepines for the relief of breathlessness intensity.87 88
The most common side- effects of benzodiazepines were 
drowsiness and somnolence, which were significantly 
more frequent compared with placebo but less frequent 
compared with morphine.84 Patients with cancer having 
breathlessness are at high risk of delirium, and the use of 
benzodiazepines may compound this concern.
It has been hypothesised that benzodiazepines may 
improve the coping capacity or reduce the unpleasantness 
related to breathlessness by a better coping of anxiety. 
However, the studies cited above measured intensity of 
breathlessness alone. There is a need for well- conducted 
and adequately powered studies measuring predictors 
and symptoms associated with breathlessness that may be 
modulated by benzodiazepines.
In the last days of life, some patients may continue to 
experience severe breathlessness despite maximising all 
other palliative measures within the limited time frame. 
In these unique situations, palliative sedation may be 
considered to alleviate suffering. Benzodiazepines such 
as midazolam infusion and/or lorazepam may be titrated 
carefully to reduce consciousness as little as possible while 
maximising comfort.89 90 This should only be considered 
a treatment of last resort and only after careful discussion 
with patients/families. When given to patients with only 
days of life expectancy, palliative sedation has not been 
associated with shorter survival.91 92
Corticosteroids
The efficacy of systematic steroids for the relief of cancer- 
related breathlessness was investigated in a system-
atic review of two RCTs.93 The first RCT, a placebo- 
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dexamethasone among 41 patients with cancer on the 
reduction of breathlessness intensity 'now' as the primary 
outcome (NRS 0–10, subscale of the Edmonton Symptom 
Assessment System (ESAS), Modified Dyspnoea Borg 
Scale).94 Between- group differences were not statisti-
cally significant, although there was a significant with-
in- arm reduction of breathlessness intensity at day 4 in 
the dexamethasone group of 1.9 on ESAS (95% CI 3.3 to 
0.5; p=0.01), whereas the placebo group showed a non- 
significant reduction of 0.7 (95% CI 2.1 to 0.6; p=0.38). 
The authors concluded that dexamethasone may provide 
rapid relief from breathlessness. A larger confirmatory 
randomised trial is currently under way to examine the 
effect of dexamethasone on breathlessness in patients 
with cancer ( clinicaltrials. gov NCT03367156).
Several randomised trials have examined breathless-
ness as a secondary outcome and reported some improve-
ment.95 96
There are no published data regarding inhaled cortico-
steroids in patients with cancer, and although commonly 
used in people with asthma and COPD, the very different 
pathophysiological characteristics of the underlying 
disease would make application of indirect evidence 
questionable. From clinical experience and biological 
rationale, the use of steroids for breathlessness due to 
lymphangitis carcinomatosis or tumour- induced respi-
ratory obstruction may have positive effects, although 
evidence is insufficient.97
Supplemental oxygen
The benefit of supplemental oxygen for relief of breath-
lessness (palliative oxygen therapy) and for improving 
physical capacity and activity in daily life has not been 
established.98–100 While supplemental oxygen is indicated 
in patients with chronic severe hypoxaemia (partial pres-
sure of oxygen (PaO2) <7.4 kPa or peripheral oxygen 
saturation (SpO2) <89% at rest) to prolong life,
101 oxygen 
has not been consistently shown to relieve breathless-
ness in the palliative setting in patients with mild or no 
hypoxaemia in advanced disease98 99 including cancer.100 
Recent guidelines from the British Thoracic Society and 
the National Guideline for Palliative Care in patients 
with non- curative cancer in Germany state that palliative 
oxygen therapy is not indicated in patients with SpO2 
≥92%, and that other treatments should be considered 
first, such as treatment of underlying causes, exercise- 
based rehabilitation, a hand- held fan and opioids.101 In 
the largest double- blind RCT to date by Abernethy et al of 
patients with advanced disease (n=239; 16% with cancer) 
with no or mild hypoxaemia (PaO2 >7.3 kPa, corre-
sponding to a SpO2 >88%), there was no difference in 
breathlessness between supplemental oxygen and room 
air over 7 days.98
However, in patients with chronic breathlessness 
despite other evidence- based treatments, a trial of supple-
mental oxygen could be justified,101 based on indirect 
data that supplemental oxygen can improve exercise 
capacity and breathlessness observed during exercise 
testing in the laboratory for patients with COPD and 
interstitial lung disease.99 102 Individualised information 
and shared decision- making with patients and caregivers 
are important.101 103 If tried, supplemental oxygen should 
be re- evaluated within a few days and discontinued if the 
patient perceives no benefit.60 98 Based on RCT data98 and 
clinical experience, a cut- off for defining clinically rele-
vant hypoxaemia as SpO2 <90% is recommended.
High- flow oxygen therapy can deliver up to 60 L/min of 
humidified and heated oxygen via nasal canulae. To date, 
only one cross- over RCT study has specifically evaluated 
its effect on breathlessness in hospitalised patients with 
cancer in the palliative care setting.104 This randomised 
trial found that high- flow oxygen and bilevel positive 
airway pressure (BiPAP) were both similarly effective 
in reducing breathlessness. More research is needed to 
examine its impact on breathlessness, particularly in the 
home setting.
Non-invasive ventilation
Non- invasive ventilation (NIV) may improve both 
oxygenation and hypoventilation, while supporting 
chest wall muscles. In a randomised trial of 200 patients 
with advanced solid tumours, NIV decreased breathless-
ness compared with supplemental oxygen, especially 
in patients with hypercapnia. NIV was associated with 
lower use of rescue opioid and had an acceptable toler-
ance and safety profile.105 Another RCT reported that 
BiPAP reduced breathlessness by 3.2 (95% CI 1.3 to 5.1) 
points on a 0–10 NRS.104 However, some patients could 
not tolerate the positive pressure and there are multiple 
contraindications to NIV.
Antidepressants
Depression and anxiety are associated with increased 
breathlessness.106 107 Five RCTs (n=336) and three case 
studies (n=19) investigated antidepressants (nortriptyline, 
paroxetine, citalopram, sertraline, protriptyline) to relieve 
breathlessness mostly in patients with COPD.108–114 The 
largest randomised trial (n=223) tested sertraline against 
placebo in patients with chronic breathlessness, of whom 
around 20% had cancer.109 None of the RCTs reported 
any significant improvement in breathlessness with antide-
pressants. The three case studies reported breathlessness 
relief by citalopram, sertraline or mirtazapine.112 113 115 A 
preliminary trial of mirtazapine shows promise, although 
further investigation is needed.116
Cannabinoids
Few studies of cannabinoids for the relief of breath-
lessness have been published, evaluating small samples 
of healthy participants or patients with COPD, with no 
effect observed.117 118 A broader clinical experience and 
adequately powered clinical trials are missing.
Multimodal interventions
Recognition that breathlessness is a multidimensional 
construct leads to development of multimodal inter-
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pharmacological treatments. Specialist palliative care 
teams, because of their interdisciplinary nature and 
symptom management expertise, may be particularly 
suited to manage breathlessness.119 120
A systematic review of holistic breathlessness services 
for patients with advanced cancer and non- cancer diag-
noses identified 37 articles across 18 different services. 
Most comprised 4–6 contacts over 4–6 weeks. Commonly 
used interventions included the hand- held fan, breathing 
techniques, psychological support and relaxation tech-
niques, although there was significant variation in the 
structure and processes for these services. Meta- analyses 
of randomised trials demonstrated reductions in NRS 
distress due to breathlessness (n=324; NRS mean differ-
ence (MD) −2.30, 95% CI −4.43 to −0.16, p=0.03) and 
Hospital Anxiety and Depression Scale (HADS) depres-
sion scores (n=408, MD −1.67, 95% CI −2.52 to −0.81, 
p<0.001) compared with usual care. Statistically non- 
significant effects were observed for Chronic Respiratory 
Questionnaire mastery (n=259, MD 0.23, 95% CI −0.10 to 
0.55, p=0.17) and HADS anxiety scores (n=552, MD −1.59, 
95% CI −3.22 to 0.05, p=0.06).20 An analysis of pooled 
individual datasets (n=259) found outcomes of reduced 
mastery and distress were influenced by baseline scores 
for these variables, but not by patient diagnosis, lung 
function or health status. Therefore stratifying patients 
by levels of mastery and/or distress due to breathlessness 
appears appropriate for research and clinical services.121 
In a meta- synthesis of qualitative interviews (n=216), 
patients and carers accessing breathlessness services 
valued tailored education, self- management interven-
tions and expert staff providing person- centred, dignified 
care.20 These components should be integrated into clin-
ical practice.
Taken together, there is good evidence to support 
the use of multimodal breathlessness services. However, 
the availability of these services remains limited. In the 
absence of such dedicated services, there is good evidence 
to support that palliative care teams can improve patient 
and caregiver outcomes.122–125 Thus, a timely referral is 
recommended.
The impact of breathlessness on caregivers
There is now a substantial body of data demonstrating 
that carers of someone suffering from chronic breathless-
ness experience profound anxiety, isolation, exhaustion 
and poor sleep. This is heightened when they witness 
their loved ones having an episode of breathlessness126 127 
and feel powerless to help them. It is also clear that they 
can become exhausted from the extra physical work and 
psychological support they need to give to their loved 
one. There are no comparable controlled data to guide 
clinical teams on the most effective interventions for 
carers’ stress—although recognition and acknowledge-
ment seem to be useful first steps.119
The onset of breathlessness in cancer tends to be over 
a much shorter period than in other illnesses, giving less 
time for the patient and carer to adjust to a new reality. It 
also progresses more quickly (in spite of recent advances 
in treatment). There are some data to suggest that 
unscheduled use of clinical services may often be related 
to carer as well as patient anxiety about seemingly inexpli-
cable breathlessness.
The psychological and physical effects of the stress 
of caring for a family member with a serious illness like 
cancer are becoming recognised.128 Given the significant 
impact on caregivers, patient and carer may benefit from 
a joint assessment to examine the impact of breathless-
ness on their lives. A structured needs- assessment tool 
such as the Carer Needs Assessment Tool may be helpful.
Psychoeducational interventions may help them 
manage episodes of breathlessness, exploring what 
happens at these times with development of a ‘ritual’ 
for crises. Where possible these interventions should be 
delivered as part of a complex interdisciplinary interven-
tion. The best evidence for impact is when they are part 
of a specialist breathlessness service.119 120 The limited 
research to date suggests that these interventions may 
help reduce anxiety and distress in both patient and carer 
and mitigate the stress and health impact of long- term 
caring.129
Recommendations
Treat the underlying cause
 ► Clinicians should identify and treat any potentially 
reversible condition(s) contributing to breathlessness 
(II, A*).
Non-pharmacological symptomatic interventions
 ► Consider use of a hand- held fan directed to the face 
and inform patients of the potential mechanisms and 
benefit. This may be useful alone in people without 
hypoxaemia, or as an adjunct to those requiring 
oxygen supplementation for hypoxaemia (II, B).
 ► Advise patients on relevant breathing retraining tech-
niques and/or refer to specialist services such as a 
physiotherapist (II, B).
 ► Consider a trial of a mobility aid to assess possible 
impact on breathing during ambulation and func-
tional activities (II, B).
 ► Educate and inform patients on strategies including 
activity pacing, relieving positions and distraction 
techniques to encourage self- management (II, B).
 ► Refer patients to available exercise- based rehabilita-
tion programmes, including pulmonary or cardiac 
rehabilitation for patients with comorbid chronic 
lung or heart disease (I, A).
 ► Provide individualised advice on aerobic and resist-
ance exercises, suitable to the patient’s functional 
status and degree of limiting breathlessness (II, B).
 ► Consider a therapeutic trial of acupressure or 
acupuncture according to patient preference (II, C).
Pharmacological symptomatic interventions
 ► Regular, oral, low- dose morphine is the first- line 
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breathlessness, which persists despite non- 
pharmacological measures (II, B).
 ► In opioid- naïve patients, a starting daily dose of sched-
uled morphine 10–30 mg over 24 hours can be used, 
with individual titration depending on the patient’s 
symptoms (II, B).
 ► In opioid- tolerant patients, an increase in the baseline 
dose of opioid by 25%–50% may be considered (V, C).
 ► In opioid- tolerant patients with severe exertional 
breathlessness associated with defined triggering 
situations leading to significant functional impair-
ment and/or distress despite standard treatments, 
consider prophylactic use of opioids prior to the 
episodes. Patients should use prophylactic doses 
sparingly (e.g. ≤2×/day) and only with close moni-
toring given that the long- term safety risk is not 
known (II, C).
 ► All patients starting opioids should be offered proph-
ylaxis for constipation with laxatives and, as needed, 
antiemetics (I, A).
 ► Patients on opioids for breathlessness should be 
educated on safe opioid use and monitored longitu-
dinally with various risk mitigation strategies (III, A*).
 ► Because of significant risk of sedation and delirium, 
benzodiazepines should not be used for breathless-
ness as first- line pharmacological therapy (III, D).
 ► Benzodiazepines may be used with caution in patients 
with cancer for the relief of breathlessness with associ-
ated anxiety if opioids are not effective (V, C).
 ► In the last days of life, benzodiazepines may be consid-
ered for palliative sedation in patients with refractory 
breathlessness despite other treatments (IV, C).
 ► Corticosteroids may be considered for palliation of 
cancer- related breathlessness refractory to other treat-
ments (II, C).
 ► Palliative oxygen is not recommended in patients with 
resting SpO2 ≥90% (II, D).
 ► High- flow oxygen therapy may be considered in 
selected patients for treatment of breathlessness, 
especially if they have hypoxaemic respiratory failure 
(II, B).
 ► A therapeutic trial for NIV can be considered in 
patients with cancer with severe chronic breathless-
ness, especially in patients with acute hypercapnic 
respiratory failure (II, B).
 ► Sertraline is not recommended for chronic breath-
lessness (II, D).
 ► The use of other antidepressants for breathlessness 
should only be limited to the clinical trials context at 
this time (V, C).
 ► The use of cannabinoids for chronic breathlessness 
is not recommended given the insufficient evidence 
and potential adverse event profile (IV, D).
Multimodal interventions
 ► Patients with cancer with chronic breathlessness 
should be referred to specialist multimodal breath-
lessness services if available (I, A).
 ► Timely referral to palliative care services should be 
considered in centres in which holistic breathlessness 
services are not available (II, B).
The impact of breathlessness on caregivers
 ► The oncology team should routinely assess the 
psychological status, information needs, and support 
network for carer(s) of breathless individuals with 
cancer (III, B*).
 ► A properly implemented caregiver needs- assessment 
tool may be helpful (II, B).
 ► Consider making referrals to specialist breathlessness 
services for patients suffering from breathlessness and 
their carers (I, A).
METHODOLOGY
These clinical practice guidelines were developed in 
accordance with the ESMO standard operating procedures 
for clinical practice guidelines development http://www. 
esmo. org/ Guidelines/ ESMO- Guidelines- Methodology. 
The relevant literature has been selected by the expert 
authors. Levels of evidence and grades of recommenda-
tion have been applied using the system shown in online 
supplemental table S1), available at ESMO Open online.130 
The * notation is assigned to the grade of recommen-
dation for statements on topics for which clinical trials 
are not available because they are inherently difficult to 
design or not justified due to ethical reasons while these 
statements are considered justified by standard clinical 
practice by the experts and the ESMO faculty.
Statements without grading were considered justified 
standard clinical practice by the experts and the ESMO 
faculty.
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In the context of progressive cancer, parenchymal metastasis, lymphangitic 
carcinomatosis, airway obstruction, pleural effusion, pneumonia, pulmonary embolism 
and atelectasis are common causes of breathlessness. These changes may activate 
chemoreceptors both centrally and peripherally, as well as mechanoreceptors, 
juxtacapillary receptors, irritant receptors and chest wall receptors peripherally [1-3]. The 
afferent signals converge in ‘respiratory centre’ the medulla, which further project to the 
ventroposterior thalamus and then the somatosensory cortex where breathlessness 
‘intensity’ is perceived, plus the limbic system (amygdala and medial dorsal thalamus) 
which contributes to an affective component of breathlessness (‘unpleasantness’) [3]. The 
reported breathlessness is further modulated by factors such as cognitions, beliefs, 
emotional well-being and culture.  
 
One of the key mechanisms contributing to breathlessness is neuromechanical 
dissociation [4, 5]. As the medullary respiratory centre senses abnormalities in breathing, 
there is a compensatory respiratory drive in the pre-Botzinger complex to increase 
respiratory effort. However, because of the underlying pathology, the respiratory 
mechanics are unable to respond adequately, resulting in a mismatch in ventilatory supply 
and demand. This neuromechanical dissociation is perceived as breathlessness. This 
understanding has important implications for treatment. For example, opioids may 
alleviate breathlessness by reducing the heightened respiratory drive, while non-invasive 
ventilation may help by improving respiratory mechanics. 
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Characterisation of breathlessness 
Breathlessness is often characterised as episodic or continuous [6, 7]. In a Delphi study, 
episodic breathlessness is defined as one form of breathlessness characterised by a 
severe worsening of breathless intensity or unpleasantness beyond usual fluctuations in 
the patient’s perception. Episodes are time limited (seconds to hours) and occur 
intermittently, with or without underlying continuous breathlessness [8]. The majority of 
patients (70%–80%) presenting with breathlessness report having episodic 
breathlessness several times daily [9-11]. The most common form of episodic 
breathlessness is exertional breathlessness, triggered by physical activities such as 
walking, climbing stairs or bathing [12]. Examples of other triggers include a change in 
position, cold weather or anxiety [8]. 
 
Continuous breathlessness is the constant, relentless sensation of shortness of breath 
that is present even at rest. Continuous breathlessness is associated with poorer survival 
than episodic breathlessness alone [13], and these patients often have significant 
functional limitations to minimise further episodic breathlessness. In one study of 70 
cancer patients with breathlessness, 61% reported having episodic breathlessness only, 
20% both episodic and continuous breathlessness and 19% reported having continuous 
breathlessness only [9]. Patients with chronic episodic or continuous breathlessness often 
limit their activities significantly to avoid worsening respiratory distress. 
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Assessment of breathlessness 
Why assess in clinical practice? 
Despite the widespread impact and prognostic information of chronic breathlessness [14-
17], routine assessment in clinical practice remains rare. A systematic review of quality 
standards in oncology care found that measurement of physical aspects of care 
comprised only 36% of quality measures and, of these, just over a quarter were related 
to breathlessness [18]. Measurement of breathlessness is now included as a consensus 
core patient-centred outcome measure set in lung cancer [19], but implementation is 
inconsistent. A growing body of evidence suggests that regular assessment with patient-
reported outcomes is associated with improvement in symptom control (including 
breathlessness) [20], quality of life (QoL) and survival [21]. 
 
Patient-reported outcomes 
i) Unidimensional assessments. Visual analogue scales (VAS; 100mm; 0 = no 
breathlessness, 100 = worse possible breathlessness) are easy to use and validated 
[22]. However, they cannot be used verbally or over the phone and many patients 
prefer the numerical rating scale (NRS). The NRS (0 to 10 where 0 = no 
breathlessness, 10 = worse possible breathlessness) is commonly used, is validated 
against the VAS, is more repeatable than the VAS and can be incorporated into 
practice [23, 24]. The NRS can be used alone for breathlessness or used as part of 
the Edmonton Symptom Assessment Scale [25]. This is useful given that people with 
cancer rarely have breathlessness alone. The VAS and NRS have a defined minimal 
clinical important difference for intensity of chronic breathlessness [26, 27]. A third 
unidimensional measure is the modified Borg scale. Used most commonly in non-
cancer disease, it is a 0 to 10 semi-ratio scale with categorical descriptors for some 
numbers. Lastly, the verbal Likert scale is quick and intuitive even to the few patients 
who struggle to give a numerical score. A recent study related NRS and Likert scales: 
0–3 (mild); 4–7 (moderate); >7 (severe) [28]. To avoid missing breathlessness in 
patients comfortable at rest, these tools can be framed ‘over the last 24 hours, how 
bad was your breathlessness at its worst?’ or ‘over the past 24 hours, how bad was 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) ESMO Open
 doi: 10.1136/esmoopen-2020-001038:e001038. 5 2020;ESMO Open, et al. Hui D
ESMO Breathlessness  Supplementary material 
4 
 
your breathlessness on average?’. The use of unidimensional tools is preferred in 
clinical practice because of ease of administration and interpretation.  
ii) Multidimensional. A full discussion of the multidimensional breathlessness tools is 
beyond the scope of this guideline and most are research rather than clinical tools. 
Two notable exceptions are the Cancer Dyspnoea Scale (CDS) [29] and the 
Dyspnoea-12 [30, 31]. Both have been developed with clinical practice in mind, but it 
is yet to be demonstrated how acceptable and feasible they are in the clinic and their 
responsiveness to change. 
iii) Functional impact. The modified Medical Research Council (mMRC) breathlessness 
scale measures the impact of breathlessness on physical exertion and is common in 
research and clinical practice across diseases. It is poorly responsive to change, and 
is not recommended to monitor treatment response, but it is useful for identifying 
patients with limiting breathlessness. In those with advanced disease, the Dyspnoea 
Exertion Scale (DES) is more discriminatory than the mMRC, with less of a ceiling 
effect [32]. 
iv) Although patient-reported outcome of breathlessness remains the gold standard, 
patients with cognitive impairment, disorders of consciousness or requiring intubation 
may not be able to self-report their subjective symptom of breathlessness. The 
Respiratory Distress Observational Scale (RDOS) was developed and validated for 
clinical use [33], and uses eight items of observation (heart rate, respiratory rate, 
restlessness, paradoxical breathing, use of accessory muscles of respiration, 
grunting, nasal flaring and a look of fear). It has low to moderate association with 
subjective breathlessness [34]. 
 
Functional tests 
i) Functional tests offer a standardised means to assess the impact of breathlessness 
on physical performance. Although breathlessness is a common limiting symptom, 
weakness, fatigue and pain can also limit test performance. A patient-reported 
assessment of the main limiting symptom at test endpoint can help to contextualise 
findings. Most functional tests have a floor or ceiling effect, so it is important to select 
a test that suits the physical capacity of the patient. Walking tests with a fixed time 
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duration may have poor utility in patients with high levels of functional impairment due 
to breathlessness [35]. 
ii) Practical tests suited to the clinic include the Timed Up and Go, 6-minute walk test or 
shuttle walk tests. The Timed Up and Go measures the time taken for patients to stand 
up from a chair, walk 3 metres at their normal pace, turn around, walk back again, and 
sit down [36]. For the 6-minute walk, patients walk at their own pace, aiming to walk 
as far as possible within 6-minutes, slowing down or stopping if necessary. In contrast 
to the 6-minute walk test which is effort dependent, the shuttle walk tests are externally 
paced and either stress the patient to a symptom-limited maximal performance 
(incremental), or by walking at a set individualised speed for as long as possible 
(endurance). The 6-minute walk, incremental and endurance shuttle walk tests have 
established psychometric properties for exercise capacity in lung cancer [37-41]. It is 
important to adhere to technical specifications when administering these tests and to 
include familiarisation runs [42]. 
iii) Poor test performance is associated with more rapid functional decline, treatment-
related complications and decreased survival in patients with cancer [43]. In patients 
with high levels of functional impairment, the loss of independence in activities of daily 
living (ADL) becomes highly relevant [44]. The London Chest Activities of Daily Living 
Scale (LCADL) measures the impact of breathlessness on both activity and social 
functioning and is acceptable, reliable and valid in patients with advanced disease and 
chronic breathlessness [45]. 
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Treatment of underlying causes 
Malignant pleural effusions 
The median survival of patients with malignant pleural effusion is 4–6 months [46]. 
Dyspnoea is the most common symptom associated with malignant pleural effusion. 
Although therapeutic thoracentesis provides effective symptom relief, most malignant 
effusions recur within a month. Repeated thoracentesis is associated with a higher risk of 
pneumothorax and empyema, and reduced efficacy due to pleural adhesions. Therefore, 
simple thoracentesis should only be provided for patients with poor performance status 
and short life expectancy.  
 
For patients with recurrence effusions and longer life expectancy (>3 months), drainage 
followed by instillation of a sclerosant or insertion of a semi-permanent tunnelled pleural 
catheter may be considered. The chest cavity can be drained surgically via thoracoscopy 
or at the bedside with a simple chest tube. Thoracoscopy was associated with greater 
comfort than a chest tube and can facilitate diagnosis of pleural involvement. For 
successful pleurodesis, the underlying lung must re-expand, and pleural apposition must 
occur. Both techniques may be used for instillation of sclerosant into the pleural space. A 
2016 Cochrane systematic review found that talc poudrage was more effective than 
bleomycin and tetracycline, with a higher rate of pleurodesis [47]. 
 
Tunnelled pleural catheter compares favourably with pleurodesis for palliation of 
breathlessness. In head-to-head randomised trials, tunnelled pleural catheter was 
associated with significant improvement in breathlessness when compared to talc 
pleurodesis despite lower pleurodesis success rate [48, 49]. Daily fluid draining via 
tunnelled pleural catheter was associated with higher rate of autopleurodesis compared 
with drainage every other day [50]. Tunnel pleural catheter was associated with fewer 
hospitalisations but higher rates of complications mostly related to catheterisation [49]. 
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Patients with central airway obstruction can present with severe acute breathlessness. 
Urgent measures to open up the airway can result in rapid improvement in 
breathlessness. In general, proximal airway lesions are better managed with 
endobronchial interventions, such as bronchoscopy with mechanical debridement, 
tumour ablation and airway stent placement, while distal obstruction (lobar or segmental 
bronchi) is more amenable to radiotherapy (RT) [51].  
 
Airway stents can re-establish the bronchial lumen and provide symptomatic 
breathlessness relief in 80%–90% of cases. Metal stents are generally used for malignant 
central airway obstruction, although silicone stents are sometimes used. Multimodality 
therapeutic bronchoscopy was found to improve breathlessness, QoL, pulmonary 
function and physical function significantly in prospective studies [52, 53]. Complications 
of stents occur in 1%–36% of patients, including haemoptysis, stent migration, retention 
of secretion, growth or overgrowth of tumour and granulation tissue formation [54]. 
 
For RT, patients who have a poor performance status and shorter survival may benefit 
from shorter fractionation schedules, e.g. 20 Gy in five fractions, 17 Gy in two weekly 
fractions, or 10 Gy in one fraction. External beam RT (EBRT) or brachytherapy can be 
associated with life-threatening complications, with a mortality rate of 7% and 15%, 
respectively [54]. 
 
Cytotoxic chemotherapy-induced pulmonary toxicities 
Pulmonary injury induced by chemotherapeutic agents may include pneumonitis, non-
cardiogenic pulmonary oedema and acute respiratory distress syndrome (ARDS). The 
histological presentations can be different and include diffuse alveolar damage, 
organising pneumonia and neutrophilic alveolitis. These toxicities may occur weeks to 
months after treatment initiation. 
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The clinical manifestations are non-specific and may include breathlessness, cough 
(typically non-productive), low-grade fever, hypoxaemia and sometimes weight loss. 
Chest imaging may help to narrow the differential diagnosis.  
The treatment of chemotherapy-induced pulmonary toxicity includes systemic 
glucocorticoids and discontinuation of the causative agent. Once a diagnosis is 
established, re-challenge with the same agent is generally not recommended because 
recurrences are expected and can be fatal [55]. 
 
Immunotherapy-induced pulmonary toxicities 
Pneumonitis is a relatively rare but potentially life-threatening complication of 
immunotherapeutic agents [anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-
4), anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death-ligand 1 
(anti-PD-L1) agents]. The incidence of pneumonitis reported in clinical trials varied 
between 3% and 7% for any grade and 1% and 3% for grade 3 or higher toxicities [56-
58]. In one retrospective study, 64 of 1826 (3.5%) cancer patients on checkpoint inhibitors 
were identified to have interstitial lung disease (Grade 2–3 66%; Grade 4, 9%; Grade 5, 
9%) [59]. 
  
The treatment approach consists of stopping the immunotherapy and introducing 
systemic corticosteroids. These are often given for 2–4 weeks, followed by a gradual 
taper over an additional 4 weeks. Most lung alterations are steroid responsive and will 
resolve within 3 months. In case of severe, steroid-refractory lung toxicity, the use of 
immunosuppressive agents, such as infliximab or cyclophosphamide, should be 
considered. However, larger pooled trials have reported that these patients often 
succumb to acute respiratory failure from pneumonitis or, more often, secondary 
opportunistic infections as a consequence of immunosuppression [60]. 
 
RT-induced lung injury 
Although modern radiation techniques have allowed a reduction of the dose administered 
to the normal lung tissue, acute radiation pneumonitis and late lung fibrosis remain 
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significant dose-limiting complications of RT, affecting 7%–37% of patients who undergo 
definitive radiation for lung cancer [61]. 
 
Because of high rate of infection in these patients, prophylactic use of antibiotics is 
considered in some patients. Corticosteroids, due to their anti-inflammatory effects, are 
used for treatment of symptomatic radiation pneumonitis at the dose of 60–100 mg/day 
for 2–4 weeks (generally 1 mg/kg of prednisone), followed by an extended tapering over 
6–12 weeks. Relapse is possible following the response to steroids. Patients with chronic 
pulmonary fibrosis should be referred to a pulmonologist for further management.  
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Opioid-related adverse effects and safe opioid use 
Low-dose regular, oral morphine extended release (ER) for chronic breathlessness, 
under carefully monitored conditions, seem to have an acceptable safety profile, with no 
serious adverse events including no events of serious respiratory depression seen in 
randomised clinical trials (RCTs) [62], opioid-related hospitalisations or deaths [63, 64]. 
There has been no large safety study in patients with cancer, but low-dose opioids [up to 
30 mg of morphine equivalent daily dose (MEDD)] were not associated with increased 
risk of hospitalisation or death in patients with end-stage chronic obstructive pulmonary 
disease (COPD) [65] or interstitial lung disease (ILD) [66]. 
 
Well-known opioid side-effects include bowel dysfunction (e.g. constipation, bloating, 
increased gastric reflux), nausea and vomiting and drowsiness. These side-effects are 
often temporal (except constipation when untreated); worst at the start of therapy and are 
reversible upon dose adjustment or discontinuation [63]. On starting opioid treatment, all 
patients should be offered a laxative for prophylaxis and treatment of constipation and an 
‘as needed’ antiemetic (such as metoclopramide or other antidopaminergic medication) 
with adequate follow-up [67]. 
 
In the era of opioid epidemics in many countries, clinicians and patients may be 
concerned about opioid use even if prescribed for an appropriate indication [68]. The 
panel would like to emphasise that for cancer patients suffering from chronic 
breathlessness, opioids remain the first choice among pharmacological options for 
palliation. The potential benefits of opioids should be balanced, in the light of the still 
limited evidence base, against the potential risks of adverse effects and risk of opioid-use 
disorders in each individual patient. Although opioids are generally well tolerated, 
respiratory depression and overdoses have been reported when opioids were not taken 
appropriately [69]. Clinicians can optimise the benefit-risk ratio by educating patients on 
safe opioid use, providing longitudinal monitoring and incorporating various risk mitigation 
strategies [70]. Referral to an interdisciplinary palliative care team may be helpful for 
patients on opioids because of the emphasis on patient education [71] and structured 
multidimensional interventions to prevent and manage non-medical opioid use [72]. 
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Supplementary Table S1. 
 
Table S1. Level of evidence and grades of recommendationa,b 
Levels of evidence  
I  Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for bias) or meta-analyses of well- 
conducted randomised trials without heterogeneity  
II  Small randomised trials or large randomised trials with a suspicion of bias 
(lower methodological quality) or meta-analyses of such trials or of trials 
with demonstrated heterogeneity  
III  Prospective cohort studies  
IV  Retrospective cohort studies or case-control studies  
V  Studies without control group, case reports, expert opinions  
Grades of recommendation  
A  Strong evidence for efficacy with a substantial clinical benefit, strongly 
recommended 
B  Strong or moderate evidence for efficacy but with a limited clinical benefit, 
generally recommended  
C  Insufficient evidence for efficacy or benefit does not outweigh the risk or 
the disadvantages (adverse events, costs, etc.) optional 
D  Moderate evidence against efficacy or for adverse outcome, generally not 
recommended  
E  Strong evidence against efficacy or for adverse outcome, never 
recommended  
 
aReprinted by permission of the Infectious Diseases Society of America [73] 
bThe * notation is assigned to the grade of recommendation for statements on topics for 
which clinical trials are not available because they are inherently difficult to design or not 
justified due to ethical reasons while these statements are considered justified by 
standard clinical practice by the experts and the ESMO Faculty. 
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